Section II - Hormonal causes

Clinical Pediatrics

Volumn 35, Issue 11, 1996, Pages 579-590

  Sotos, Juan F ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; GROWTH HORMONE; OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; ARTICLE; CHILD GROWTH; CLINICAL FEATURE; ECTOPIC HORMONE PRODUCTION; GALLSTONE FORMATION; GIGANTISM; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; INTRAMUSCULAR DRUG ADMINISTRATION; RADIOSURGERY; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION; ADENOMA; ADOLESCENT; ADULT; ANIMAL; CHILD; FEMALE; HYPERPLASIA; HYPOPHYSIS; HYPOPHYSIS TUMOR; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; REVIEW; SECRETION;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; FEMALE; GIGANTISM; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPERPLASIA; MALE; PITUITARY GLAND; PITUITARY NEOPLASMS;

EID: 0030278693     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Sotos JF, Romshe CA. Giantism and Acromegaly. In: Gardner L, ed. Endocrine and Genetic Diseases of Childhood. Philadelphia: WB Saunders Co; 1975.
2. Daughaday WH. Pituitary gigantism. Endocrinol Metab Clin North Am. 1992; 21:633-647.
3. Blumberg DL, Sclar CA, David R, et al. Acromegaly in an infant. Pediatrics. 1989;83:998-1002.
4. Vogl TJ, Nerlich A, Dresel SH, Bergman C. CT of the "Tegernsee Giant": juvenile gigantism and polyostotic fibrous dysplasia. J Computer Assist Tomogr. 1994;18:319-322.
5. Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 1992;120:931-934.
6. Lu PW, Silink M, Johnston I, et al. Pituitary gigantism. Arch Dis Child. 1992; 67:1039-1041.
7. Iwatani N, Kodama M, Seto H. A child with pituitary gigantism and precocious adrenarche: does GH and/or PRL advance the onset of adrenarche? Endocrinol Jpn. 1992;39:251-257.
8. Matsuura H, Kitazawa Y, Tanaka M, Morooka K. Pituitary adenoma and unexpected sudden infant death: a case report. Med Pediatr Oncol. 1994; 22:283-286.
9. Fazekas I, Pasztor E, Slowik F, et al. Pathological and experimental investigations in a case of gigantism. Acta Neuropathol. 1993;85:167-174.
10. Zimmerman D, Young WF Jr, Ebersold MJ, et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 1993;76: 216-222.
11. Moran A, Asa SL, Kovacs K, et al. Gigantism due to pituitary mammosomatotroph hyperplasia. New Engl J Med. 1990;323:322-327.
12. Araki Y, Sakai N, Andoh T, et al. Central neurocytoma presenting with gigantism: case report. Surg Neurol. 1992;38:141-145.
13. Cuttler L, Jackson JA, Saeed us-Zafar M, Levitsky LL. Hypersecretion of growth hormone and prolactin in Mc-Cune-Albright syndrome. J Clin Endocrinol Metab. 1989;68:1148-1154.
14. von Werder K, Losa M, Stalla GK, et al. Long-term treatment of a metastasizing GRFoma with a somatostatin analogue (SMS 201-995) in a girl with gigantism. Scand J Gastroenterol. 1986; 119 (Suppl 21):238.
15. Espiner EA, Carter TAH, Abbott GD, Wrightson P. Pituitary gigantism in a 31 month old girl: endocrine studies and successful response to hypophysectomy. J Endocrinol Invest. 1981;4: 445-450.
16. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol. 1980;12:71-79.
17. Hayles AB. Gigantism. Pediatr Ann. 1980;9:163-169.
18. Joishy SK, Morrow LB. McCune-Albright syndrome associated with a functioning pituitary chromophobe adenoma. J Pediatr. 1976;89:73-75.
19. Lightner ES, Penny R, Frasier SD. Pituitary adenoma in McCune-Albright syndrome: follow-up information. J Pediatr. 1976;89:159.
20. Nakagawa H, Nagasaka A, Sugiura T, et al. Gigantism associated with McCune-Albright's syndrome. Horm Metab Res. 1985;17:522-527.
21. Kovacs K, Horvath E, Thorner MO, Rogol AD. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Archiv (Patholog Anat Histopathol). 1984;403:77-84.
22. Asa SL, Scheithouer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab. 1984;58:796-803.
23. Bevan JS, Asa SL, Rossi ML, et al. Intrasellar gangliocytoma containing gastrin and growth hormone-releasing hormone associated with a growth hormone-secreting pituitary adenoma. Clin Endocrinol. 1989;30:213-224.
24. Gilsanz Peral A, Gomez Balaguer M, Alberola Carbonell C, et al. Evidencia de la production por un tumor carcinoide pulmonar del factor liberador de la hormona del crecimiento causante de acromegalia. Med Clinica. 1987;89:789-792.
25. Glikson M, Gil-Ad I, Galum E, et al. Acromegaly due to ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumour. Dynamic hormonal responses to various stimuli. Acta Endocrinol. 1991; 124:366-371.
26. Faglia G, Arosio M, Bazzoni N. Ectopic acromegaly. Endocrinol Metab Clin North Am. 1992;21:575-595.
27. Melmed S. Etiology of pituitary acromegaly. Endocrinol Metab Clin North Am. 1992;21:539-552.
28. Thorner MO, Vance ML, Horvath K, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams' Textbook of Endocrinology, 8th ed. Philadelphia: WB Saunders Co; 1992.
29. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987;330:566-568.
30. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of G, and stimulate adenylyl cyclase in human pituitary tumors. Nature. 1989;340:692-696.
31. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome. New Engl J Med. 1991;325:1688.
32. Bystrom C, Larsson C, Blomberg C, et al. Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Nat Acad Sci USA. 1990;87:1968-1972.
33. Asa SL, Kovacs K. Pituitary pathology in acromegaly. Endocrinol Metab Clin North Am. 1992;21:553-574.
34. Nelson C, Albert VR, Elsholtz HP, et al. Activation of cell-specific expression of rat growth hormone and prolactin genes by a common transcription factor. Science. 1988;239:1400-1405.
35. Melmed S. Acromegaly. N Engl J Med. 1990;322:966-977.
36. Hartman ML. The adverse systemic effects of growth hormone in acromegaly. Growth Genet Horm. 1990;6:1-5.
37. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-299.
38. Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 1982;300: 611-615.
39. Hammer RE, Brinster RL, Rosenfeld MG, et al. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature. 1985;315:413-416.
40. Quaife CJ, Mathews LS, Pinkert CA, et al. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology. 1989; 124:40-48.
41. Chang-De Moranville BM, Jackson IMD. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am. 1992;21:649-668.
42. Hindmarsh PC, Pringle PJ, Brook CG. The 24-hour growth hormone secretion in a boy with giantism. Acta Endocrinol. 1988;117:403-408.
43. Hartman ML, Veldhuis JD, Vance ML, et al. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab. 1990;70:1375-1384.
44. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B. Evaluation of acromegaly by radioimmunoassay of somato-rnedin-C. N Engl J Med. 1979;301: 1138-1142.
45. Melmed S, Ziel FH, Braunstein GD, et al. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. J Clin Endocrinol Metab. 1988;67:395-399.
46. Moller DE, Moses AC, Jones K. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. J Endocrinol Metab. 1989;68:499.
47. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992; 21:669-692.
48. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary-adenoma in a series of 214 patients. J Neurosurg. 1988;68:854-867.
49. Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992;21:693-712.
50. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol, Biol, Phys. 1980;6: 1215-1228.
51. Soni SS, Marten GW, Pitner SE, et al. Effects of central-nervous-system irradiation on neuropsychologic functioning of children with acute lymphocytic leukemia. N Engl J Med. 1975; 293:113-118.
52. Shalet SM, Beardwell CG, Morris-Jones P, et al. Growth hormone deficiency in children with brain tumors. Cancer. 1976;37(Suppl 2):1144-1148.
53. Eiser C. Intellectual abilities among survivors of childhood leukaemia as a function of CNS irradiation. Arch Dis Child. 1978;53:391-395.
54. Kliman B, Kjellberg RN, Swisher B, et al. Proton beam therapy of acromegaly: a 20-year experience. In: Black PM, Zervas NT, Ridgway EC, et al, eds. Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy, vol 1. New York: Raven; 1984:191-211.
55. Lamberts SW. The role of somato-statin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988;9:417-436.
56. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am. 1992;21:737-752.
57. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med. 1991;151: 1573-1578.
58. Heron I, Thomas F, Dero M, et al. Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog. Presse Med (Paris). 1993;22:526-531.
59. Melmed S, Ho K, Klibanski A, et al. Clinical Review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995;80:3395.
60. Morangi I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994;79:145-151.
61. Marek J, Hana V, Krsek M, et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol. 1994;131:20-26.
62. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992; 21:713-736.
63. Kocijancic A, Prezelj J, Vrhovec I, Lancranjan I. Parlodel IAR in the treatment of macroprolactinomas. Acta Endocrinol. 1990;122:272-276.
64. Jaffe CA, Friberg RD, Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest. 1993;92:695-701.